NCT06972641 - Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2030

Conditions

AMLMDS

Interventions

DRUG

Decitabine

Decitabine 3.5 mg/m2 1-5d for 28 days for 6 cycles of dosing

DRUG

Sorafenib (BAY-43-9006)，giritinib

Sorafenib 0.2g 2/day or giritinib 40mg 2/day orally for 2 years

DRUG

Avastinib

100 mg 1/day

DRUG

Venetoclax;Selenisol

Vinaclat: 50-100mg 1/day orally, d1-14 1/day per month (adjust drug dosage based on blood levels), 28-day cycle; Selenisol: 20mg qw orally (weeks 1 and 2), 28-day cycle If the above treatment is not tolerated, adjust the regimen to decitabine 3.5 mg/m2 1-5 d; 28 days as a cycle of 6 cycles of medication; Vinaclat: 50-100 mg 1/day orally, d1-14 1/day per month orally (adjust the dose of the drug according to the blood concentration), 28 days as a cycle of medication

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER